AF
CLYM

Amalgamated Financial’s Climb Bio CLYM Stock Holding History

Amalgamated Financial’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$9K Buy
+1,039
New +$9.69K ﹤0.01% 2916

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Amalgamated Financial's CLYM Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Climb Bio (CLYM) in Q1 2022: 1,039 shares worth $9K. The stake represents ﹤0.01% of the portfolio and ranks #2916 among its holdings.

43 funds tracked by Wall St. Rank hold CLYM as of Q1 2022.

  • Amalgamated Financial held 1,039 shares of Climb Bio worth $9K as of Q1 2022.
  • Climb Bio was a new Amalgamated Financial position in Q1 2022.
  • Climb Bio made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2916 holding.
  • 43 funds tracked by Wall St. Rank held Climb Bio as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.